Short URL: openmetaanalysis.github.io/asthma

View the Project on GitHub (for authors)

Clinical summary: This meta-analysis suggests that the clinical intervention is effective regardless of baseline eosinophil count. The heterogeneity was 'substantial' (I2 = 62%) and is not clinically explained.

We included randomized controlled trials of treating adult patients with severe asthma with tezepelumab. Additional interpretations may be in the references in the 'Cited by' section below.

Acknowledgement: we acknowledge the essential work by the authors of the prior systematic review(s) listed below.

Methods overview: This repository is an openMetaAnalysis that combines methods of scoping, rapid, and living systematic reviews. This analysis updates one or more previously published review(s)(1).

  Newer studies included are listed in the references. Rationale for newer trials excluded may be listed at the end of the references.

A comparison of studies included in this review compared to prior reviews are in the table, reconciliation of studies included with prior meta-analyses. Studies were abstacted into standardized tables of , and results.

Results: Details of the studies included are in the:

Below is the forest plot for the primary outcome. Additional Forest plots may be available. Image of forest plot of primary outcome

Below is a subgroup analysis for the primary outcome. Additional subgroup plots may be available.
Image of subgroup meta-analysis of primary outcome
Below is a blobbogram that includes related studies for the primary outcome.
Image of a blobbogram of primary outcome

References:

Systematic review(s)

Most recent review(s) at time of last revision of this repository

  1. Edris A, De Feyter S, Maes T, Joos G, Lahousse L. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis. Respir Res. 2019 Aug 8;20(1):179. doi: 10.1186/s12931-019-1138-3. PMID: 31395084; PMCID: PMC6688359 Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017 Sep 21;9(9):CD010834. doi: 10.1002/14651858.CD010834.pub3. PMID: 28933516; PMCID: PMC6483800. Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, Gaga M, Kellermeyer L, Khurana S, Knight S, McDonald VM, Morgan RL, Ortega VE, Rigau D, Subbarao P, Tonia T, Adcock IM, Bleecker ER, Brightling C, Boulet LP, Cabana M, Castro M, Chanez P, Custovic A, Djukanovic R, Frey U, Frankemölle B, Gibson P, Hamerlijnck D, Jarjour N, Konno S, Shen H, Vitary C, Bush A. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020 Jan 2;55(1):1900588. doi: 10.1183/13993003.00588-2019. PMID: 31558662.

Studies

New Studies not included in the review(s) listed above

  1. Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, Brightling CE, Griffiths JM, Hellqvist Å, Bowen K, Kaur P, Almqvist G, Ponnarambil S, Colice G. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med. 2021 May 13;384(19):1800-1809. doi: 10.1056/NEJMoa2034975. PMID: 33979488.

Studies included in the most recent review above

  1. Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, van der Merwe R. Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med. 2017 Sep 7;377(10):936-946. doi: 10.1056/NEJMoa1704064. Erratum in: N Engl J Med. 2019 May 23;380(21):2082. PMID: 28877011.

Studies undergoing review

  1. Wechsler ME, Ruddy MK, Pavord ID, Israel E, Rabe KF, Ford LB, Maspero JF, Abdulai RM, Hu CC, Martincova R, Jessel A, Nivens MC, Amin N, Weinreich DM, Yancopoulos GD, Goulaouic H. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N Engl J Med. 2021 Oct 28;385(18):1656-1668. doi: 10.1056/NEJMoa2024257. PMID: 34706171.

Studies excluded - selected list of important studies
  1. None

Funding for this review

  1. None.

Cited by

This repository is cited by:

  1. Taleb AA, Badgett RG. In severe, uncontrolled asthma, tezepelumab reduced exacerbations and improved asthma control at 1 y. Ann Intern Med. 2021 Oct;174(10):JC115. doi: 10.7326/ACPJ202110190-115. Epub 2021 Oct 5. PMID: 34606305.